Revenue and Volume Growth
Net sales of $480 million, up 8% year-over-year; organic volumes up 3% YoY. Adjusted EBITDA of $73 million, a 5% increase YoY. Non-GAAP diluted EPS $1.63, up 3% YoY.
Consistent Market Share Gains
Net share gains of 4% (top of target range); this is the 10th consecutive quarter of net share gains and the company outperformed end markets estimated down ~1% in the quarter.
Asia Pacific Outperformance
Asia Pacific sales increased ~25% YoY driven by ~10% organic volume growth, Dipsol acquisition contribution and ~3% favorable FX. Asia segment earnings rose ~32% (~$8 million) YoY.
Gross Margin Improvement
Gross margins improved sequentially by ~150 basis points and were ~40 basis points higher YoY, reported near 36.8% (near the high end of the 36%-37% target range) driven by higher asset utilization and operational performance.
Balance Sheet and Liquidity Strengthening
Amended credit agreement extended nearest maturity to April 2031 (from June 2027), increased revolving availability by ~$300 million and right to increase by ~$331 million; cost of debt ~5% and interest expense stable at ~$10 million in Q1.
Transformation Program and Identified Cost Savings
Announced transformation to reduce cost/complexity with expected ~ $10 million of new run-rate savings exiting 2026 and a clear path to at least $20-$30 million of sustainable structural cost improvement over the next 3 years. Dortmund closure expected to deliver ~$2 million in 2026 and ~$5 million annual run-rate beginning 2027.
Acquisition Contribution and Integration Progress
Acquisitions (notably Dipsol) contributed ~4% to net sales in Q1 and will be part of organic base starting Q2; acquisition-related synergies and expanded product portfolio are supporting share gains.
Operational Investments and Capex Discipline
Q1 capex of ~$11 million (primarily the new China facility); full-year 2026 capex guidance maintained at ~2.5%-3.5% of sales. New Zhongjuang facility expected to improve efficiency and local manufacturing capability in Asia.